Acadia Pharmaceuticals (ACAD) Current Assets (2010 - 2026)

Acadia Pharmaceuticals' Current Assets history runs 17 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• In Q1 2026, Current Assets rose 25.84% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 25.84% YoY), while the FY2025 annual figure was $1.1 billion, up 13.19% from the prior year.
• Current Assets was $1.1 billion for Q1 2026 at Acadia Pharmaceuticals, up from $1.1 billion in the prior quarter.
• In the past five years, Current Assets ranged from a high of $1.1 billion in Q1 2026 to a low of $492.6 million in Q2 2023.
• Historically, Current Assets has averaged $730.1 million across 5 years, with a median of $675.3 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Current Assets decreased 19.55% in 2022, then jumped 57.92% in 2024.
• A 5-year view of Current Assets shows it stood at $507.9 million in 2022, then rose by 21.3% to $616.1 million in 2023, then jumped by 52.29% to $938.3 million in 2024, then advanced by 13.19% to $1.1 billion in 2025, then climbed by 3.19% to $1.1 billion in 2026.
• The last three Current Assets figures came in at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.